WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? Read more about WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?
Self-reported weight at birth predicts measures of femoral size but not volumetric BMD in eldery men: MrOS. Read more about Self-reported weight at birth predicts measures of femoral size but not volumetric BMD in eldery men: MrOS.
Novel methods to evaluate fracture risk models. Read more about Novel methods to evaluate fracture risk models.
Effects of denosumab on fracture and bone mineral density by level of kidney function. Read more about Effects of denosumab on fracture and bone mineral density by level of kidney function.
Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. Read more about Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial.
IGF-1R signaling in chondrocytes modulates growth plate development by interacting with the PTHrP/Ihh pathway. Read more about IGF-1R signaling in chondrocytes modulates growth plate development by interacting with the PTHrP/Ihh pathway.
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. Read more about Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Read more about Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. Read more about Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. Read more about Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
